drugset
drugset / Trial / NCT06660056

A Phase I Clinical Study of Intratumoral Injection GC001 in Patient With Recurrent or Progressive Gliomas

NCT06660056 ↗

Phase 1 Recruiting 35 enrolled GONGCHU Biotechnology Co., Ltd
Non-randomizedSequentialOpen-labelTreatment

Summary

A Phase I Study Evaluating the Safety, Tolerability, Biodistribution and Shedding of the Virus, Pharmacodynamics, Immunogenicity, and Antitumor Activity of GC001 Oncolytic Vaccinia Virus Injection in Patient With Recurrent or Progressive Gliomas .

Timeline

Start
2024-10-08
Primary completion
2026-02-08
Completion
2026-08-08

Drugs

EvaluationDrugModalityDoseRoute
Subject GC001 Other / unclassified 1e+06 unknown Intrathecal
Subject GC001 Other / unclassified 3e+06 unknown Intrathecal
Subject GC001 Other / unclassified 1e+07 unknown Intrathecal
Subject GC001 Other / unclassified 1e+09 unknown Intrathecal

Indications

malignant glioma